Akebia Therapeutics, Inc. (AKBA)
NASDAQ: AKBA · Real-Time Price · USD
1.910
-0.020 (-1.04%)
At close: Mar 28, 2025, 4:00 PM
1.915
+0.005 (0.27%)
After-hours: Mar 28, 2025, 4:12 PM EDT
Akebia Therapeutics Revenue
In the year 2024, Akebia Therapeutics had annual revenue of $160.18M, down -17.70%. Akebia Therapeutics had revenue of $46.50M in the quarter ending December 31, 2024, a decrease of -17.26%.
Revenue (ttm)
$160.18M
Revenue Growth
-17.70%
P/S Ratio
2.54
Revenue / Employee
$884,972
Employees
181
Market Cap
451.20M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 160.18M | -34.44M | -17.70% |
Dec 31, 2023 | 194.62M | -97.86M | -33.46% |
Dec 31, 2022 | 292.48M | 80.83M | 38.19% |
Dec 31, 2021 | 211.65M | -82.99M | -28.17% |
Dec 31, 2020 | 294.64M | -40.36M | -12.05% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionAKBA News
- 3 days ago - Akebia Therapeutics Announces Poster Presentations at NKF Spring Clinical Meetings 2025 - GlobeNewsWire
- 8 days ago - JOYY, Akebia Therapeutics, Microchip Technology And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
- 8 days ago - Akebia Therapeutics Announces Pricing of Public Offering of Common Stock - GlobeNewsWire
- 9 days ago - Akebia Therapeutics Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 15 days ago - Akebia Therapeutics, Inc. (AKBA) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 15 days ago - Akebia Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Vafseo® (vadadustat) Commercial Launch Progress Update - GlobeNewsWire
- 22 days ago - Akebia Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Discuss Recent Business Highlights - GlobeNewsWire
- 23 days ago - Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire